PMA device
Guardian Connect System
Medtronic Minimed · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Mar 8, 2018, newest Oct 9, 2025Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
13
Naming "Guardian Connect"
MAUDE reports
2
Brand "Guardian Connect", since 2015
PubMed studies
15
Mentioning "Guardian Connect"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Guardian Connect System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Guardian Connect SystemPMA supplement
P160007-S054 · Decided Oct 9, 2025 · 55 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
- Guardian Connect SystemPMA supplement
P160007-S029 · Decided May 20, 2020 · 177 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P160007 · Decided Mar 8, 2018 · 730 days after receipt
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Guardian Connect", any status and sponsor, newest update first.
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT04910841 · 55 participants (planned) · Start Sep 11, 2023 · Primary completion Sep 2026
Device: CGM GUARDIAN 2 · For: Hyperglycemia; Hypotension; Shock, Septic
Sites: Nice, France
- Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the HospitalPivotal-lookingCompleted
Shanghai 6th People's HospitalAcademic, hospital or other
NCT05941286 · 533 participants · Start Apr 18, 2024 · Primary completion Dec 16, 2024
Device: CGM system with both glucose predictive alerts and threshold alerts on; CGM system with only glucose threshold alerts on and 1 more · For: Diabetes Mellitus
Sites: Shanghai, China
Medtronic MiniMed, Inc.Public (MDT)
NCT04809285 · 217 participants · Start Apr 6, 2021 · Primary completion Sep 29, 2023
Device: Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app · For: Type 1 Diabetes Mellitus
Sites: Little Rock, Arkansas; Loma Linda, California; Newport Beach, California · 14 sites in all
10 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Guardian Connect", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
MW5105701 · Received Dec 1, 2021 · Event dated Nov 20, 2021
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Product Quality Problem; Problem with Software Installation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
MW5096437 · Received Sep 3, 2020 · Event dated Jul 27, 2020
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Device Alarm System
Patient problem as coded: Hypoglycemia
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Medtronic, Simplera Sensor, REF: MMT-5100JD1Open, Classified
Z-0033-2026 · Started May 7, 2025 · Posted by FDA Oct 2, 2025
Reason given: The device cap label may not adhere to the sensor, compromising the sterility of the sensor, and increasing the risk of infection.
Cause as FDA categorized it: Process design · Device type: Sensor, Glucose, Invasive (MDS)
- Guardian Connect App CSS7200 iOS and Guardian Connect Transmitter GST4C used on the iPhone, iPad and iPod Touch devices.Open, Classified
Z-2106-2020 · Started May 20, 2019
Reason given: Customers using the firm's continuous glucose monitoring system application on an iPhone, iPad or iPod Touch with ios software version 12, 12.1, or 12,2 are likely to experience a shortened transmitter battery life (approximately 4-5 days instead of the normal 7 days or more) after a full charge.
Cause as FDA categorized it: Software design · Device type: Sensor, Glucose, Invasive (MDS)
Z-1282-2019 · Started Jul 4, 2018
Reason given: The application may be closed by the operating system without alerting the user the app is no longer running or communicating with the transmitter resulting in the user not receiving alerts that could be associated with hypoglycemic or hyperglycemic events.
Cause as FDA categorized it: Software design · Device type: Sensor, Glucose, Invasive (MDS)
Published research
The most relevant PubMed records for "Guardian Connect"[tiab]. The summary above synthesizes these.
- Evaluation of a Fourth-Generation Subcutaneous Real-Time Continuous Glucose Monitor (CGM) in Individuals With Diabetes on Peritoneal Dialysis.
Ng JKC, Ling J, Luk AOY, et al. · Diabetes Care · 2023Research Support, Non-U.S. Gov't
- Impact of Body Composition and Anemia on Accuracy of a Real-Time Continuous Glucose Monitor in Diabetes Patients on Continuous Ambulatory Peritoneal Dialysis.
Ling J, Ng JKC, Lau ESH, et al. · Diabetes Technol Ther · 2024Research Support, Non-U.S. Gov't
- A head-to-head comparison between Guardian Connect and FreeStyle Libre systems and an evaluation of user acceptability of sensors in patients with type 1 diabetes.
Yeoh E, Png D, Khoo J, et al. · Diabetes Metab Res Rev · 2022Research Support, Non-U.S. Gov't
- Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts.
Abraham SB, Arunachalam S, Zhong A, et al. · J Diabetes Sci Technol · 2021Research Support, Non-U.S. Gov't
- Glycemic variability is associated with diastolic dysfunction in patients with type 2 diabetes.
Dzhun Y, Mankovsky G, Rudenko N, et al. · J Diabetes Complications · 2023
- Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor.
Christiansen MP, Garg SK, Brazg R, et al. · Diabetes Technol Ther · 2017Research Support, Non-U.S. Gov't
- Performance and Usability of Three Systems for Continuous Glucose Monitoring in Direct Comparison.
Freckmann G, Link M, Kamecke U, et al. · J Diabetes Sci Technol · 2019Comparative Study, Research Support, Non-U.S. Gov't
- Feasibility of Real-Time Continuous Glucose Monitoring Telemetry System in an Inpatient Diabetes Unit: A Pilot Study.
Dillmann C, Amoura L, Fall Mostaine F, et al. · J Diabetes Sci Technol · 2022
- Continuous Glucose Monitoring in Critically Ill Patients With COVID-19: Results of an Emergent Pilot Study.
Sadhu AR, Serrano IA, Xu J, et al. · J Diabetes Sci Technol · 2020
- Artificial intelligence in the management of metabolic disorders: a comprehensive review.
Anwar A, Rana S, Pathak P · J Endocrinol Invest · 2025Review
- Optimizing Perioperative Glycaemic Control with Continuous Glucose Monitoring in Pregestational Diabetes: Feasibility and Comparative Analysis of Two Systems: A Pilot Study.
Kacperczyk-Bartnik J, Urban A, Bartnik P, et al. · J Clin Med · 2025
- Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes.
Slover RH, Tryggestad JB, DiMeglio LA, et al. · Diabetes Technol Ther · 2018Multicenter Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
- Guardian RtMedtronic Minimed · PMA 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.